Cancer

Anti-angiogenic tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib)

Small molecules that block the receptors through which tumours recruit new blood vessels; used in advanced renal cell carcinoma.

Mechanism of action

Molecular targets

Drugs in Anti-angiogenic tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib)

Therapeutic uses

Diseases it treats

Adverse effects

Contraindications by condition

Other cautions and interactions

Connected topics

Written from

Educational reference. Not medical advice, diagnosis or treatment.